

# **Spreeta**<sup>TM</sup> The Binding of Neutravidin Followed by the Attachment of Biotinylated Antibodies to the Spreeta Surface



Number 004



Microcomponents Technology

#### **IMPORTANT NOTICE**

Texas Instruments and its subsidiaries (TI) reserve the right to make changes to their products or to discontinue any product or service without notice, and advise customers to obtain the latest version of relevant information to verify, before placing orders, that information being relied on is current and complete. All products are sold subject to the terms and conditions of sale supplied at the time of order acknowledgement, including those pertaining to warranty, patent infringement, and limitation of liability.

TI warrants performance of its semiconductor products to the specifications applicable at the time of sale in accordance with TI's standard warranty. Testing and other quality control techniques are utilized to the extent TI deems necessary to support this warranty. Specific testing of all parameters of each device is not necessarily performed, except those mandated by government requirements.

CERTAIN APPLICATIONS USING SEMICONDUCTOR PRODUCTS MAY INVOLVE POTENTIAL RISKS OF DEATH, PERSONAL INJURY, OR SEVERE PROPERTY OR ENVIRONMENTAL DAMAGE ("CRITICAL APPLICATIONS"). TI SEMICONDUCTOR PRODUCTS ARE NOT DESIGNED, AUTHORIZED, OR WARRANTED TO BE SUITABLE FOR USE IN LIFE-SUPPORT DEVICES OR SYSTEMS OR OTHER CRITICAL APPLICATIONS. INCLUSION OF TI PRODUCTS IN SUCH APPLICATIONS IS UNDERSTOOD TO BE FULLY AT THE CUSTOMER'S RISK.

In order to minimize risks associated with the customer's applications, adequate design and operating safeguards must be provided by the customer to minimize inherent or procedural hazards.

TI assumes no liability for applications assistance or customer product design. TI does not warrant or represent that any license, either express or implied, is granted under any patent right, copyright, mask work right, or other intellectual property right of TI covering or relating to any combination, machine, or process in which such semiconductor products or services might be or are used. TI's publication of information regarding any third party's products or services does not constitute TI's approval, warranty or endorsement thereof.

Copyright © 1999, Texas Instruments Incorporated

## The Binding of Neutravidin Followed by the Attachment of Biotinylated Antibodies to the Spreeta<sup>™</sup> Surface

#### ABSTRACT


This process describes the binding of neutravidin to a clean gold surface followed by the attachment of functionally active biotinylated antibodies to the surface of the Texas Instruments ( $TI^{TM}$ ) Spreeta sensor, which is included in the Spreeta Evaluation Kit (formerly known as the *TISPR-1 Experimenter's Kit*<sup>†</sup>).

### Introduction

There are many different ways to attach antibodies (and other bio-recognition elements) to the surface of a Spreeta sensor. This application brief provides one protocol for use with biotinylated antibodies. As with all bio-attachment procedures, this one may not be suitable for your particular application; further optimization may be necessary.

### **Surface Cleaning**

Before attaching any bio-recognition elements to the surface of the Spreeeta sensor, a gold surface cleaning procedure should be performed (see TI Application Brief 002, *Gold Spreeta™ Sensor Surface Cleaning*). For example, rinse the surface with phosphate buffered saline (PBS) for a few minutes and then switch over to a NaOH/Triton X-100 solution for approximately two minutes. Then, switch back to PBS and establish a good baseline (<1e–5/min), as shown in Figure 1.



NOTES: 1. A = The baseline with PBS running buffer

B = The application of 0.12 N NaOH in 1% Triton X-100

C = The new baseline with PBS running buffer on the cleaned gold surface


2. The refractive index shift between A and C (approximately  $1.5 \times 10^{-3}$ ) is typical, but will depend on how dirty the gold surface was prior to cleaning.

### Figure 1. In-Situ Cleaning of the Spreeta Gold Surface

<sup>†</sup> This test kit is being sold by Texas Instruments (TI) for experimental purposes only and not for commercial use. Spreeta and TI are trademarks of Texas Instruments Incorporated.

### **Surface Avidination**

When the gold surface has been cleaned, and a steady PBS baseline has been established, begin flowing a 50-ug/ml solution of neutravidin in PBS. You should then see a normal protein binding curve. A total refractive index increase of between 1 and  $2 \times 10^{-3}$  should occur within five minutes. Revert to PBS, and less than 5% of the bound neutravidin should rinse off, as shown in Figure 2.



NOTES: 1. A = The baseline with PBS running buffer

- B = The application of 20 ug/ml neutravidin in PBS
- C = The new baseline with PBS running buffer on the cleaned gold surface
- 2. The refractive index shift between A and C (approximately 2 × 10<sup>-3</sup>) is typical, but depends on how clean the gold surface was prior to avidination.


### Figure 2. Binding of Neutravidin to a Clean Spreeta Gold Surface

### **Biotinylated Antibody Attachment**

Antibodies are often available for purchase in a biotinylated form; but, they can also be biotinylated using a simple procedure that minimizes the degree of biotinylation and reduces the likelihood of modifying the antigen binding site. Such a procedure was used to produce biotinylated anti-dinitrophenol (DNP) antibodies for this work[1].

To attach an anti-DNP antibody, apply approximately 3 ml of a 3 ug/ml solution of biotinylated anti-DNP antibody in PBS to the avidinated Spreeta surface at a flow rate of approximately 0.3 ml/min.

This is sufficient to saturate the avidinated surface, as seen from the protein binding curve shown in Figure 3. A refractive index increase of approximately  $1 \times 10^{-3}$  is seen and very little of the antibody is rinsed off after you have switched back to the normal PBS running buffer. These values are typical.




NOTES: 1. A = The baseline with PBS running across a neutravidinated surface B = The application of 3 ug/ml biotinylated anti-DNP antibodies in PBS C = The new baseline with PBS running buffer

2. The refractive index shift between A and C (approximately  $1.2 \times 10^{-3}$ ) is typical.

Figure 3. Binding of Biotinylated Anti-DNP Antibodies to a Neutravidinated Spreeta Gold Surface

### **Evaluation of Antibody Activity**

Following antibody attachment, a PBS/Triton X-100 baseline should be established. Triton X-100 is used to help reduce non-specific binding (NSB) antigen. In this case, 10 ug/ml DNP-bovine serum albumin (BSA) in PBS/0.1% Triton X-100 is applied to the surface. The resulting antigen-binding curve is obtained with a refractive index increase of approximately  $5 \times 10^{-4}$ , as shown in Figure 4.



NOTES: 1. A = The baseline with PBS + 0.1% Triton X-100 running across surface coated with biotinylated anti-DNP antibodies B = The application of 3 ug/ml DNP-BSA, also in PBS + 0.1% Triton X-100

C = The new baseline with PBS + 0.1% Triton X-100 running buffer

2. The refractive index shift between A and C (approximately  $5\times10^{-4}$  ) is typical.

### Figure 4. Binding of DNP-BSA to Biotinylated Anti-DNP on a Spreeta Gold Surface

## Controls

Blocking agents such as BSA can be used following surface avidination as well as after antibody attachment. Also, antibody attachment can be performed in the presence of 0.1% Triton X-100. Specificity was generally checked at appropriate times using BSA and other irrelevant proteins, and NSB was always less than 3% of specific binding for this system.

### Summary

The procedure described here demonstrates one method for attaching functionally active antibodies to the Spreeta surface. This procedure may be modified to incorporate any one of a vast assortment of antibodies, although levels of activity will vary. More information on Spreeta is available at www.ti.com/spreeta. Send all questions and comments to spreeta@ti.com.

### References

- 1. Wolf, C. and D.S. Hage, "Studies on the rate and control of antibody oxidation by periodate" *Analytical Biochemistry*, **231**, 123–130, 1995.
- 2. Spreeta Evaluation Kit User's Guide, Texas Instruments Incorporated, Dallas, September 1999.